Women with breast cancer, particularly those who are older and who receive adjuvant chemotherapy, are at significantly increased risk for mild cognitive impairment (MCI). Our previous research shows persistent and progressive MCI long after cancer treatment has ended. This cognitive impairment tends to involve difficulties with memory and executive function (i.e. multi-tasking, problem solving) that interfere with daily livin skills and reduce quality of life. The default mode network (DMN) is a brain circuit important for normal cognitive function. The connections between the DMN brain regions tend to naturally decrease in strength as we age. DMN functional connectivity has been demonstrated to be a highly promising neuroimaging biomarker of MCI in non-cancer populations. Disruption of DMN functional connectivity is strongly associated with conversion to dementia and has even been show to precede other biomarkers of neurodegeneration. Previous studies, including our own, show atrophy of DMN regions and damage to the white matter pathways that connect these regions following breast cancer chemotherapy. We believe that chemotherapy treatment accelerates DMN decline resulting in increased frequency of MCI following breast cancer. However, no studies to date have directly assessed the DMN or its relationship to MCI in breast cancer.
The specific aims of the proposed study are therefore to 1) determine the frequency of MCI in older breast cancer subjects who receive chemotherapy, 2) identify DMN neuroimaging biomarkers in older breast cancer subjects treated with chemotherapy, and 3) develop models that predict vulnerability to MCI in this population. We will accomplish these aims by integrating longitudinal multidimensional neuropsychological assessments of cognitive function, mood and behavior with advanced, non-invasive multimodal magnetic resonance imaging techniques and APOE genotyping. We will evaluate 55 women with primary breast cancer prior to chemotherapy, one month following chemotherapy and six months following chemotherapy. We will compare the chemotherapy-treated group to 55 women with breast cancer who do not receive chemotherapy and 55 healthy females, all matched on important demographic and clinical factors. All groups will be assessed at the same time intervals. We will emphasize the assessment of memory and executive function as well as DMN functional connectivity. We will incorporate clinical, demographic, psychiatric (e.g. depression, fatigue) and genetic (e.g. APOE) factors with DMN connectivity into our predictive models of MCI. Identifying neuroimaging biomarkers underlying chemotherapy-related MCI will improve identification of individuals at highest risk for neurodegeneration and aid the development of treatments for these impairments. This is of critical importance given an aging society and the increased incidence of and vulnerability to both breast cancer and MCI.

Public Health Relevance

Women with breast cancer who receive chemotherapy are at significantly increased risk for mild cognitive impairment (MCI) which reduces quality of life and extends disease-related disability. The proposed study aims to identify neuroimaging biomarkers of MCI in these women and develop methods to help predict which women are most vulnerable. This research is highly relevant to breast cancer, one of the most common public health problems, affecting 1 in 8 women.

National Institute of Health (NIH)
National Institute of Nursing Research (NINR)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZNR1)
Program Officer
Tully, Lois
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
United States
Zip Code
Moruno-Manchon, Jose F; Uzor, Ndidi-Ese; Kesler, Shelli R et al. (2018) Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol Cell Neurosci 86:65-71
Hansen, Chase C; Smith, Joshua B; Mohamed, Abdallah S R et al. (2017) Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. Head Neck 39:2048-2056
Kesler, Shelli R; Noll, Kyle; Cahill, Daniel P et al. (2017) The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol 131:565-574
Kesler, Shelli R; Rao, Vikram; Ray, William J et al. (2017) Probability of Alzheimer's disease in breast cancer survivors based on gray-matter structural network efficiency. Alzheimers Dement (Amst) 9:67-75
Noll, Kyle R; Bradshaw, Mariana E; Weinberg, Jeffrey S et al. (2017) Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology 26:617-624
Hosseini, S M Hadi; Pritchard-Berman, Mika; Sosa, Natasha et al. (2016) Task-based neurofeedback training: A novel approach toward training executive functions. Neuroimage 134:153-159
Noll, Kyle R; Ziu, Mateo; Weinberg, Jeffrey S et al. (2016) Neurocognitive functioning in patients with glioma of the left and right temporal lobes. J Neurooncol 128:323-31
Moruno-Manchon, Jose Felix; Uzor, Ndidi-Ese; Kesler, Shelli R et al. (2016) TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging (Albany NY) 8:3507-3519
Kesler, Shelli R; Blayney, Douglas W (2016) Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. JAMA Oncol 2:185-92
Wefel, Jeffrey S; Noll, Kyle R; Rao, Ganesh et al. (2016) Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 18:1656-1663

Showing the most recent 10 out of 21 publications